Randomization access [Regulatives / Guidelines]

posted by bkrao  – India, 2015-08-10 12:18 (3619 d 02:24 ago) – Posting: # 15209
Views: 5,091

Thanks you.

I required few more suggestions in this regard.

If analyst knows the treatment received by the subject, then the analysis bias is open thing know?

Then the study will be a result oriented, analyst driven study, we can call. but its should not be actual outcome required by the regulatory i hope, kindly suggest.


Thanks you & Regards,
Balaga Koteswara Rao,
Cadila Pharmaceuticals Ltd.

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,682 registered users;
61 visitors (0 registered, 61 guests [including 18 identified bots]).
Forum time: 14:43 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5